Definium Therapeutics US
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Definium Therapeutics US sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Definium Therapeutics US: 6 sponsored US clinical trials, 4 recruiting.
Definium Therapeutics US sponsors 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 1 completed. 4 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Generalized Anxiety Disorder, with 2 trials.
Upper-quartile sponsor footprint
Definium Therapeutics US sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
NCT07592689
A Phase 2A Trial of MM402 for Autism Spectrum Disorder
NCT07303907
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06809595
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
NCT06741228
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
NCT06941844
A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms
NCT05407064
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 4 |
Therapeutic Areas
Where Definium Therapeutics US enrollment is open (later-stage tilt)
4 recruiting of 6 indexed (67% open); 1 completed (17%).
Phase mix: 4 late (III/IV) vs 2 early (I/II) (later-stage heavy).
Top condition: Generalized Anxiety Disorder (2 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Definium Therapeutics US: open-pipeline peers nationwide
Peers matched on 6 registered trials and 67% open enrollment, not the therapeutic-area sidebar.
Definium Therapeutics US sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 67% open enrollment (± trial volume)
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
- Advanced Reconstructive Surgery Alliance · 67% recruiting · 3 trials
- Alexander B Olawaiye, MD · 67% recruiting · 3 trials
Related
What to do with this Definium Therapeutics US page
6 registered trials is a research-attention snapshot, not an endorsement of Definium Therapeutics US or any single study.
- 4 of Definium Therapeutics US's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Generalized Anxiety Disorder is the condition Definium Therapeutics US studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Generalized Anxiety Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Definium Therapeutics US pipeline card: 6 registered trials from official public datasets.Report a data error.